• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aptose Bioscns (NQ: APTO )

    0.3950 -0.0050 (-1.25%)
    Streaming Delayed Price Updated: 11:49 AM EDT, Sep 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aptose Bioscns

    < Previous 1 2 Next >
    Aptose Announces Results from Special Meeting of Shareholders
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
    Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Adjournment of its Special Meeting of Shareholders
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Reports Results for the Second Quarter 2024
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Receipt of Deficiency Notice from Nasdaq
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Results from Annual and Special Meeting of Shareholders
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Reports Results for the First Quarter 2024
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Reports Results for the Fourth Quarter and Full Year 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Reports Results for the Third Quarter 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
    Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
    Company to Hold Clinical Update Webcast; Details Forthcoming 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Present at the Cantor Global Healthcare Conference
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
    — TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Reports Results for the Second Quarter 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Presents Highlights from Clinical Update
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.